NLX meaningful response was defined on the basis of a 25 % improvement in the first phase average 1 NLX-P101 study . Patients in the sham surgery arm of the study, which meet all the conditions remain the opportunity to receive NLX-P101 is provided in a planned cross-over study. Treated subjects continue to be evaluated in an open-label, long-term follow-up study.. The primary endpoint was the difference in UPDRS motor scores between NLX – P101 and sham – treated patients when the subjects were off PD medication.

Results:? The 18 people lost a total of 156 pounds, 143 of them in body fat. People lost an average of 8.8 pounds – 90 % of that was fat. Triglycerides decreased by an average of 37 %. The nine participants who had expressed a desire to lose weight lost an average of 15.This information has been out of kaiserhealthnews.org courtesy from the Henry J. Kaiser Family Foundation. It can move the entire Kaiser Daily Health Policy Report, search the archives and log to email delivery on Emperor HealthNews.